Related Experiment Video

Updated: Dec 7, 2025

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.4K

Ticagrelor prevents tumor metastasis via inhibiting cell proliferation and promoting platelet apoptosis

Xingjun Meng1, Weisheng Liu1, Hui Yang1

  • 1The Affiliated Suzhou Hospital of Nanjing Medical University.

Anti-Cancer Drugs
|October 3, 2020
PubMed

Insights

Ticagrelor, an antiplatelet drug, inhibits tumor cell proliferation and metastasis. This study shows ticagrelor induces platelet apoptosis, suggesting its potential as an anti-tumor agent against cancer spread.

Area of Science:

  • Oncology
  • Hematology
  • Pharmacology

Background:

  • Tumor cells interact with and activate platelets, promoting tumor survival and spread.
  • Inhibiting platelet activity or platelet-tumor cell interactions is a therapeutic strategy for cancer progression.

Purpose of the Study:

  • To investigate the anti-tumor effects of ticagrelor, a novel antiplatelet medication.
  • To evaluate ticagrelor's impact on tumor cell proliferation, migration, invasion, and metastasis.

Main Methods:

  • In vitro studies using B16F10 and Lewis lung carcinoma cell lines.
  • Assessment of ticagrelor's effect on tumor cell proliferation, migration, and invasion.
  • In vivo experiments to evaluate ticagrelor's efficacy in reducing tumor metastasis.

Main Results:

  • Ticagrelor significantly inhibited proliferation, migration, and invasion of tested cancer cells.
  • Ticagrelor induced dose-dependent apoptosis in platelets.
  • In vivo studies confirmed that ticagrelor treatment reduced tumor metastasis.

Conclusions:

  • Ticagrelor exhibits potent anti-proliferative and anti-metastatic effects on cancer cells.
  • Ticagrelor's induction of platelet apoptosis contributes to its anti-tumor activity.
  • Ticagrelor shows promise as a potential therapeutic agent for combating tumor metastasis.

More Related Videos

Ferric Chloride-induced Murine Thrombosis Models10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

22.7K
Adaptation of Semiautomated Circulating Tumor Cell CTC Assays for Clinical and Preclinical Research Applications14:14

Adaptation of Semiautomated Circulating Tumor Cell CTC Assays for Clinical and Preclinical Research Applications

Published on: February 28, 2014

16.1K

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
910
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.3K
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
6.2K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.4K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.3K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.7K